Brief: Clinuvel Pharmaceuticals Says Two Grounds Of Appeal Upheld By Nice Panel
30/06/2023 02:34
June 30 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* TWO GROUNDS OF APPEAL UPHELD BY NICE PANEL
* ENGLAND'S NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE LOST
A SECOND INTERNAL APPEAL
* LOST SECOND INTERNAL APPEAL FOLLOWING DECISION NOT TO
RECOMMEND
AFAMELANOTIDE FOR USE ON ENGLISH NATIONAL HEALTH SERVICE
Source text for Eikon: ID:nASXbJx9Qp
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist